Dr. Susanne B. Breitkopf

Dr. Susanne B. Breitkopf has extensive experience in the field of proteomics and mass spectrometry. Dr. Susanne B. is currently working as a Principal Scientist at Kymera Therapeutics since August 2021. Prior to that, they worked at Pfizer as a Senior Scientist Proteomics from May 2017 to July 2021, where they provided support for various scientific projects related to proteomics, phosphoproteomics, protein-protein interactions, and chemical labeling.

Before joining Pfizer, Dr. Breitkopf served as an Instructor at Harvard Medical School, BIDMC from January 2015 to May 2017. Their research focused on developing a personalized medicine strategy based on protein-protein interactions and using mass spectrometry for profiling cancer cell metabolism. Dr. Susanne B. also conducted research as a Post-Doc at Harvard Medical School, BIDMC from July 2010 to January 2015, where they studied protein-protein interactions in multiple myeloma and investigated the role of a secreted tyrosine kinase in the extracellular environment.

Dr. Breitkopf's academic journey began as a Ph.D. student at the Max Planck Institute of Biochemistry from January 2007 to June 2010. Their research during this time involved the study of leukemia cell lines and the identification of potential therapeutic targets using quantitative phosphoproteomics analysis.

Overall, Dr. Susanne B. Breitkopf's work experience showcases their expertise in proteomics, mass spectrometry, protein-protein interactions, and cancer research.

Dr. Susanne B. Breitkopf obtained a Diploma in Biology from Ludwig-Maximilians-Universität München, from 2001 to 2006.